SCHEMBL646463

SCHEMBL646463

COC(=O)c1cc(Br)c(OCc2ccccc2)cc1OCc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 2/20 0.53
HPGD P15428 2/20 0.51
LMNA P02545 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.49
SMPD1 P17405 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
FFAR4 Q5NUL3 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
RAB9A P51151 2/20 0.48
PTPN1 P18031 1/20 0.47
FOLH1 Q04609 1/20 0.47
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 3/20 0.46
NPC1 O15118 1/20 0.46
POLB P06746 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16616227 0.95 SMN1; SMN2 (0.55) ABCB1HPGDLMNASMN1; SMN2KDM4E
SCHEMBL1764051 0.95 ABCB1 (0.59) ABCB1HPGDLMNAL3MBTL1SMPD1
SCHEMBL28437033 0.89 SMPD1 (0.50) ABCB1HPGDLMNAL3MBTL1SMPD1
SCHEMBL1763974 0.89 HPGD (0.56) ABCB1HPGDLMNAL3MBTL1SMPD1
SCHEMBL167312 0.89 LMNA (0.49) HPGDLMNAL3MBTL1SMPD1HDAC1
SCHEMBL24983869 0.88 LMNA (0.56) HPGDLMNASMPD1HDAC1HDAC8
SCHEMBL1976781 0.88 FFAR4 (0.51) HPGDLMNAL3MBTL1SMPD1HDAC1
SCHEMBL382869 0.87 ALDH1A1 (0.53) ABCB1L3MBTL1TDP1SMN1; SMN2RAB9A
SCHEMBL31363007 0.87 ALDH1A1 (0.53) ABCB1L3MBTL1TDP1SMN1; SMN2RAB9A
SCHEMBL383569 0.87 FOLH1 (0.60) ABCB1L3MBTL1TDP1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116751200-A Tricyclic compounds containing substituted pyridones and methods of using the same 爱彼特生物制药公司 2023-09-15 CN disclosed
CN-110114071-B Tricyclic compounds containing substituted pyridones and methods of using the same 爱彼特生物制药公司 2023-07-04 CN disclosed
EP-3534903-B1 SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2022-08-03 EP disclosed
US-11013726-B2 Substituted pyridinone-containing trycyclic compounds, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-25 US disclosed
US-11013726-B2 Substituted pyridinone-containing trycyclic compounds, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-25 US disclosed
US-10821103-B2 Substituted pyridinone-containing trycyclic compounds, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2020-11-03 US disclosed
US-10821103-B2 Substituted pyridinone-containing trycyclic compounds, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2020-11-03 US disclosed
US-20200261432-A1 SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2020-08-20 US disclosed
US-20200261432-A1 SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2020-08-20 US disclosed
US-20190314347-A1 SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. 2019-10-17 US disclosed
US-8183279-B2 1,3-dihydroisoindole derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-05-22 US disclosed
US-8119795-B2 Triazole derivatives II MERCK PATENT GMBH (DE) 2012-02-21 US disclosed
US-20100311745-A1 1,3-DIHYDROISOINDOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-12-09 US disclosed
US-20100311745-A1 1,3-DIHYDROISOINDOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-12-09 US disclosed
US-20100311745-A1 1,3-DIHYDROISOINDOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-12-09 US disclosed
US-20100113542-A1 TRIAZOLE DERIVATIVE AS AN HSP 90 INHIBITOR MERCK PATENT GESELLSCHAFT (DE) 2010-05-06 US disclosed
US-20100113542-A1 TRIAZOLE DERIVATIVE AS AN HSP 90 INHIBITOR MERCK PATENT GESELLSCHAFT (DE) 2010-05-06 US disclosed
US-20100113542-A1 TRIAZOLE DERIVATIVE AS AN HSP 90 INHIBITOR MERCK PATENT GESELLSCHAFT (DE) 2010-05-06 US disclosed
US-20100022540-A1 TRIAZOLE DERIVATIVES II MERCK PATENT GESELLSCHAFT (DE) 2010-01-28 US disclosed
WO-2008086857-A1 TRIAZOLE DERIVATIVE AS AN HSP 90 INHIBITOR MERCK PATENT GMBH (DE) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200261432-A1 SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME HAVCR2, HCCS, TYMP ABCB1 264/4885HPGD 393/4885LMNA 826/4885
US-20100022540-A1 TRIAZOLE DERIVATIVES II HSP90AB1, HSP90AA1, HSP90AB2P ABCB1 44/4885HPGD 1305/4885LMNA 3864/4885
US-20190314347-A1 SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME HAVCR2, HCCS, TYMP ABCB1 264/4885HPGD 393/4885LMNA 826/4885
US-20100113542-A1 TRIAZOLE DERIVATIVE AS AN HSP 90 INHIBITOR HSP90AB1, HSP90AB2P, HSP90AA1 ABCB1 263/4885HPGD 959/4885LMNA 3661/4885
US-11013726-B2 Substituted pyridinone-containing trycyclic compounds, and methods using same HAVCR2, HCCS, TYMP ABCB1 264/4885HPGD 393/4885LMNA 826/4885
US-20100311745-A1 1,3-DIHYDROISOINDOLE DERIVATIVES HSP90AB1, HSP90AA1, HSP90AB2P ABCB1 240/4885HPGD 811/4885LMNA 3424/4885
US-10821103-B2 Substituted pyridinone-containing trycyclic compounds, and methods using same HAVCR2, HCCS, TYMP ABCB1 264/4885HPGD 393/4885LMNA 826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.